Contributions
Abstract: EP1275
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
Pure red cell aplasia (PRCA) is considered an uncommon but critical complication after ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). Previous studies have demonstrated several risk factors for post-HSCT PRCA, such as anti-A isohemagglutinins against donor red blood cells (RBC) and reduced-intensity conditioning regimens.
Aims
We intended to evaluate the clinical outcomes in the context of ABO-incompatible transplantation using peripheral blood stem cells.
Methods
We carried out a prospective nested case-control study to determine the prevalence and factors associated with PRCA following major ABO-incompatible peripheral blood stem cell transplantation (PBSCT) between August 1, 2014 and June 30, 2020. A total of 478 patients receiving ABO-incompatible PBSCT were observed and divided into 3 cohorts, including 196 with major grafts, 214 with minor grafts, and 68 with bidirectional grafts. The nested case-control study enrolled 187 patients after major ABO-incompatible PBSCT for the detailed analysis.
Results
A total of 13 out of 187 patients developed PRCA. The factors associated with PRCA were the patient’s age, donor type, and the use of anti-T-lymphocyte globulin (ATG). Haploidentical related donor (HRD) was the only independent factor for PRCA after HSCT in the multivariate analysis (HR=0.029, 95%CI 0.004-0.231, P<0.001). The presence of PRCA did not influence overall survival (OS), disease-free survival (DFS), acute or chronic graft-versus-host disease (GVHD), non-relapse mortality (NRM), and relapse rate after HSCT.
Conclusion
The incidence of PRCA was 7% (95% CI, 3.9%>11.9%) after major ABO-incompatible PBSCT and low dose ATG-based haploidentical transplantation can significantly decrease the development of PRCA post-HSCT.
Keyword(s): ABO blood group, Haploidentical stem cell transplantation, Peripheral blood stem cell transplant, Pure red cell aplasia
Abstract: EP1275
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
Pure red cell aplasia (PRCA) is considered an uncommon but critical complication after ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). Previous studies have demonstrated several risk factors for post-HSCT PRCA, such as anti-A isohemagglutinins against donor red blood cells (RBC) and reduced-intensity conditioning regimens.
Aims
We intended to evaluate the clinical outcomes in the context of ABO-incompatible transplantation using peripheral blood stem cells.
Methods
We carried out a prospective nested case-control study to determine the prevalence and factors associated with PRCA following major ABO-incompatible peripheral blood stem cell transplantation (PBSCT) between August 1, 2014 and June 30, 2020. A total of 478 patients receiving ABO-incompatible PBSCT were observed and divided into 3 cohorts, including 196 with major grafts, 214 with minor grafts, and 68 with bidirectional grafts. The nested case-control study enrolled 187 patients after major ABO-incompatible PBSCT for the detailed analysis.
Results
A total of 13 out of 187 patients developed PRCA. The factors associated with PRCA were the patient’s age, donor type, and the use of anti-T-lymphocyte globulin (ATG). Haploidentical related donor (HRD) was the only independent factor for PRCA after HSCT in the multivariate analysis (HR=0.029, 95%CI 0.004-0.231, P<0.001). The presence of PRCA did not influence overall survival (OS), disease-free survival (DFS), acute or chronic graft-versus-host disease (GVHD), non-relapse mortality (NRM), and relapse rate after HSCT.
Conclusion
The incidence of PRCA was 7% (95% CI, 3.9%>11.9%) after major ABO-incompatible PBSCT and low dose ATG-based haploidentical transplantation can significantly decrease the development of PRCA post-HSCT.
Keyword(s): ABO blood group, Haploidentical stem cell transplantation, Peripheral blood stem cell transplant, Pure red cell aplasia